Processa Pharmaceuticals Files for $15 Million Offering

December 17, 2019

On 12/13/19 Processa Pharmaceuticals filed for a $15 million offering of common stock. The Hanover, MD based company focuses on acquiring and developing drugs that already have some proof-of-concept clinical data supporting its clinical use in the indication selected and in 2-4 years after acquisition will either have completed the pivotal study or be ready for a pivotal study and out-licensing. Processa trades on the OTCQB Marketplace under the symbol “PCSA." The company intends to apply to list its common stock on NASDAQ.

Processa's lead product, PCS-499, is an oral tablet that is an analog of an active metabolite of pentoxifylline (PTX) - trade name Trental. According to the company prospectus, "higher exposure of certain active metabolites are seen after PCS-499 administration compared to PTX. Despite the greater exposure to these pharmacologically active molecules, PCS-499 appears to be well tolerated, even at higher doses than the standard dosing of PTX."

The lead indication currently under development for PCS-499 is Necrobiosis Lipoidica (NL). NL is a chronic, disfiguring condition affecting the skin and the tissue under the skin typically on the lower extremities with no currently approved FDA treatments. Approximately 74,000 - 185,000 people in the United States and more than 200,000 – 500,000 people outside the United States are affected by NL. In June of 2018, the company announced that PCS-499 had received Orphan Drug Status from the FDA for Necrobiosis Lipoidica.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.